Here's the thing. Medicare has been legally barred from covering weight-loss medications since 2006. The Trump administration didn't wait for Congress to fix that — it built a detour.
The Bridge program, a demonstration project that launched in July 2026 and runs through December 2027, gives Medicare beneficiaries access to three GLP-1 weight-loss drugs: Zepbound (tirzepatide), Foundayo (orforglipron), and Wegovy (semaglutide). Eligible patients pay a flat $50 monthly co-pay. The federal government covers a net $245 per prescription, paid directly to drug manufacturers.
The program operates entirely outside Part D's standard payment and insurance structure — that's the legal mechanism that lets it sidestep the statutory prohibition. It's not a benefit. It's a bridge.
The eligibility rules are where things get complicated.
To qualify, a patient must have a BMI of 35 or higher — or between 27 and 35 with an obesity-related comorbidity. So far, straightforward. But CMS explicitly excludes patients who have type 2 diabetes, moderate-to-severe sleep apnea, or metabolic dysfunction-associated steatohepatitis (MASH). The rationale: those conditions already have covered indications under standard Medicare.
The practical result, as a physician noted in MedPage Today, is that a patient with a BMI of 35 whose sleep apnea tips from mild to moderate is disqualified from Bridge and redirected to their Part D plan — which may or may not cover GLP-1s, and if it does, the out-of-pocket cost could run hundreds of dollars a month.
Not every formulation qualifies either. According to Pharmacy Times, semaglutide is covered in injectable and tablet form; tirzepatide is covered only as the KwikPen — single-dose vials and other pens are explicitly excluded; orforglipron is reimbursed for all dosage strengths.
The $50 is also not as simple as it sounds.
The co-pay is flat, with no income-based exceptions. Low-income subsidy enrollees — who typically pay little or nothing under Part D — get no reduction. And the $50 does not count toward a beneficiary's deductible or out-of-pocket maximum.
The companion initiative, BALANCE — a five-year pilot designed to fold GLP-1 coverage into Part D through negotiated manufacturer pricing — has been indefinitely paused after failing to reach the required 80% plan sponsor participation threshold. Bridge is what's left standing.
CMS has not publicly detailed the total projected cost of the program, though estimates run into the billions annually.
The administration deserves credit for moving when Congress wouldn't. A 20-year-old statutory ban on Medicare obesity drug coverage was never going to fix itself, and negotiating lower net prices directly with Eli Lilly and Novo Nordisk — announced by President Trump in November 2025 — was the prerequisite that made Bridge possible at all. That's free-market leverage applied to a bureaucratic wall, and it worked, at least partially.
But a demonstration project with a hard December 2027 expiration, a paused companion program, undisclosed cost projections, and eligibility rules that can disqualify a patient for having a condition the drug is proven to treat — that's not a solution. It's a placeholder. The roadmap past 2027 does not yet exist in public view, and for the seniors counting on $50 access to continue, that uncertainty is the real fine print.
